Abstract 16722: Changes in Carotid Wall Morphology and Plaque Composition in Patients With Established Vascular Disease and Treated With Intensive Lipid Therapy in the AIM-HIGH Study
Objective: Changes in carotid wall morphology (MORPH) and plaque composition (COMP) over 2 years (yrs) of intensive lipid therapy by plaque types were investigated in AIM-HIGH.
Methods: Qualified baseline and 2-yr follow-up scans were obtained in 156 AIM-HIGH subjects. MR images were analyzed by independent Core Lab reviewers using published criteria for quantifications of MORPH and COMP. MORPH included volumes of total vessel (TVV), lumen (LV), wall (WV=TVV-LV) and fibrous tissue (FTV) in mm3 and %WV was calculated using the formula: (WV/TVV) X 100% in all available slices. COMP focused on percentages of lipid-rich necrotic core (%LRNC), FT (%FT) and calcium (%CA) calculated using the formula: (LRNC, FT or CA V/WV) x 100% using the slices containing LRNC. Of 156, 89 were in statin+placebo for extended-release niacin (ERN) and 67 in statin+ERN groups. Changes in MORPH and COMP were compared between the 2 treatment groups and between plaque types: w/o LRNC (n=76), w/ LRNC but w/o intraplaque hemorrhage (IPH) (n=62), w/ LRNC & IPH (n=18).
Results: In the 76 subjects w/o LRNC, there were significant increases in TVV (24±52 mm3/yr, p<0.001), LV (14±40 mm3/yr, p<0.01), WV (10±26 mm3/yr, p=0.002) and FTV (10±26 mm3/yr, p=0.002) while %WV was relatively stable (0.04±1.0%, p=0.48) over 2yrs. In the 62 w/ LRNC but w/o IPH, the slices containing LRNC showed a significant decrease in %LRNC (1.05±2.6%/yr, p=0.001) and significant increases in %FT (0.85±2.7%/yr, p=0.01) and %CA (0.20±0.63%/yr, p=0.002), although corresponding MORPH did not change significantly. By contrast, LRNC plaques w/ IPH tended to increase in %LRNC (1.4±3.2/yr) and decrease in %FT (1.4±3.0%/yr). These rates were significantly different from those of the LRNC plaques w/o IPH (p=0.008 and 0.012, respectively). These MORPH and COMP measures did not differ significantly between statin+placebo and statin+ERN groups.
Conclusions: Intensive lipid therapy with statin or statin plus ERN significantly associated with positive MORPH remodeling in plaques w/o LRNC. Plaques w/ LRNC experienced COMP improvement without significant MORPH changes. However, the COMP improvement was not seen in plaques w/ IPH. These results indicate that plaques in different disease stages respond to lipid therapy differently.
Author Disclosures: X. Zhao: None. T. Hatsukami: None. D. Hippe: None. D. Isquith: None. J. Sun: None. N. Balu: None. M.B. Neradilek: None. K. Yamada: None. G. Canton: None. J.R. Crouse: None. T.J. Anderson: None. J. Huston: None. N. Polissar: None. K.D. O’Brien: None. C. Yuan: None.
- © 2014 by American Heart Association, Inc.